Dragonfly Therapeutics names world leader in NK therapeutics as CSO

27 June 2017

Privately-held Cambridge, USA-based discovery-stage company Dragonfly Therapeutics has appointed Nicolai Wagtmann as its chief scientific officer (CSO).

Dr Wagtmann will head the company's scientific team and the development and commercialization of novel Natural Killer (NK) cell-based immunotherapies, using the company's proprietary TriNKET technology platform.

Dr Wagtmann joins Dragonfly's scientific co founders, Drs Tyler Jacks, head of MIT's Koch Institute for Integrative Cancer Research, and David Raulet, Schekman Chair in Cancer Biology at UC Berkeley, in leading the company's scientific programs and working with Dragonfly's scientific advisory board members.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK